SPAM-LOW: RE: [Histonet] Responses to IHC CAP Validation question

[Patsy Ruegg]

I believe the point of validating is supposed to be to use samples that are
processed in your own facility, so if you use controls you have not fixed
and processed yourself it would not be valid.

Regards,
Patsy

Patsy Ruegg, HT(ASCP)QIHC
IHCtech, LLC
Fitzsimmons BioScience Park
12635 Montview Blvd. Suite 215
Aurora, CO 80010
P-720-859-4060
F-720-859-4110
wk email pruegg <@t> ihctech.net
web site www.ihctech.net
 

This email is confidential and intended solely for the use of the Person(s)
('the intended recipient') to whom it was addressed. Any views or opinions
presented are solely those of the author. It may contain information that is
privileged & confidential within the meaning of applicable law. Accordingly
any dissemination, distribution, copying, or other use of this message, or
any of its contents, by any person other than the intended recipient may
constitute a breach of civil or criminal law and is strictly prohibited. If
you are NOT the intended recipient please contact the sender and dispose of
this e-mail as soon as possible.

-----Original Message-----
From: histonet-bounces <@t> lists.utsouthwestern.edu
[mailto:histonet-bounces <@t> lists.utsouthwestern.edu] On Behalf Of
tonia.richmond <@t> gracepathology.com
Sent: Thursday, May 06, 2010 9:28 AM
To: McMahon, Loralee A
Cc: histonet <@t> lists.utsouthwestern.edu; thisisann <@t> aol.com
Subject: SPAM-LOW: RE: [Histonet] Responses to IHC CAP Validation question


   If  you  are a brand new lab, how do you validate IHC if you are no=
   yet  receiving patient specimens?  Can the validation be done on cont
rol tissues only?




   Sincerely,


   Tonia Richmond, AS, HT (ASCP)
   Chief Operations Officer = Laboratory
   Grace Pathology
   PH:  (501) 765-7367
   Email: =1]tonia.=ichmond <@t> gracepathology.com



   -----histonet-bounces <@t> lists.utsouthwestern.edu wrote: -----
   <=FONT>

     To:        "thisisann@=      aol.com"        <thisisann <@t> aol.com>,
     "histonet <@t> lists.utsouthwestern.edu" <
;histonet <@t> lists.utsouthwestern.edu>
     From: "McMahon, Loralee A" <Lo=alee_Mcmahon <@t> URMC.Rochester.edu>
     Sent by: histonet-bounces <@t> lists.u=southwestern.edu
     Date: 04/28/2010 02:01PM
     Subject: RE: [Histonet] Re=ponses to IHC CAP Validation question
     Any  inspection  that  I have under=one we have used the 25 to 30
     case  rule.   Except  for  the Er/Pr//Her-2=  We use closer to 50
     cases.   We  also  use  a  TMA to make our live= easier.  The TMA
     contains known positives and known negatives.
     I=n  cases of t-cell or b-cell markers or cytokeratins.  25 to 30
     cases  i= easy.  But when you are validated for more hard to find
     markers  (SV-=0) then fewer cases is acceptable.  We always throw
     in  a slide that w= know will not stain for sv-40 like a tonsil -
     then you can say it has spe=ificity.
     Any  inspector that I have come across is usually understanding=f
     this.  But I am sure that there are exceptions to this.........esp
ecially if they are not familiar with immunohistochemistry.
     Loralee McMahon, HTL (ASCP)
     Immunohistochemistry Supervisor
     Strong M=morial Hospital
     Department of Surgical Pathology
     (585) 275-7210
          ______________________     5F__=5F______________
     From:          histonet-bounces <@t> lis=        ts.utsouthwestern.edu
     [histonet-bounces <@t> lists.utsouthwestern.edu]     On    Behalf=  Of
     thisisann <@t> aol.com [thisisann <@t> aol.com]
     Sent: Wednesday, April 28, 201= 2:47 PM
     To: histonet <@t> lists.utsouthwestern.edu
     Subject: [Histonet] R=sponses to IHC CAP Validation question
     The following is one respone= rec'd:
     1.   I  asked  CAP  who told me that they do not currentl= have a
     guideline on
     validating but that they
     recommend what is in t=e following book:
     Quality  Management  In  Anatomic  Pathology,  Promoting  P=tient
     Safety
     Through Systems Improvement and Error
     by Raouf E. Nakhl=h, MD & Patrick Fitzgibbons, MD editors
     sold by CAP !
     Chapter 8-=uality Management in IHC
     That is what we follow.
     I. Get a new antib=dy and optimize it with your positive control.
     II.  Once  optimized  you  n=ed to run it on cases expected to be
     positive
     (how many?)
     "a suffien= size ..."
     III. Must also be run on cases expected to be negative. (how=any?
     IV.  In a situation where you cannot expect a lot of cases or such
a
     case has
     never been presented in your lab, then you must say just =hat.
     (ex. some of the hormones we just use a pituitary)
          ___________________     ______________________     5F__=5F__
     Histonet mailing list
     Histonet <@t> lists.utsouthwestern.edu
     =2]http://lists.utsouthwestern.edu/mailman/listinfo/histonet
          ______________________     5F__     ______________________
     Histo=et mailing list
     Histonet <@t> lists.utsouthwestern.edu
     [3]http://l=sts.utsouthwestern.edu/mailman/listinfo/histonet

   
References

   1. 3D"mailto:tonia.richmond <@t> gracepathology.com"
   2. 3D"http://lists.utsouthwestern.edu/mailman/listinfo/histonet"
   3. 3D"http://=
_______________________________________________
Histonet mailing list
Histonet <@t> lists.utsouthwestern.edu
http://lists.utsouthwestern.edu/mailman/listinfo/histonet